Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash & Equivalents (2023 - 2025)

CG Oncology's Cash & Equivalents history spans 3 years, with the latest figure at $32.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 87.36% year-over-year to $32.5 million; the TTM value through Dec 2025 reached $32.5 million, down 87.36%, while the annual FY2025 figure was $32.5 million, 87.36% down from the prior year.
  • Cash & Equivalents reached $32.5 million in Q4 2025 per CGON's latest filing, down from $45.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $257.1 million in Q4 2024 to a low of $8.3 million in Q4 2023.
  • Average Cash & Equivalents over 3 years is $60.6 million, with a median of $41.5 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: soared 3009.94% in 2024, then plummeted 87.36% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $8.3 million in 2023, then skyrocketed by 3009.94% to $257.1 million in 2024, then tumbled by 87.36% to $32.5 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Cash & Equivalents are $32.5 million (Q4 2025), $45.1 million (Q3 2025), and $14.6 million (Q2 2025).